Citra Anticoagulants, Inc. announces that noCLOT-400 Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., 4 milliliters known as ACD-A, has been cleared for distribution by the United States Food 's38; Drug Administration for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the production of platelet rich plasma.
This regulatory achievement clears the way for Citra Anticoagulants to market this product in the United States. It also allows our customers to include this product in kits that they
market and distribute. noCLOT-400 joins its sister product noCLOT-50's8482; and is marketed and distributed exclusively by Citra Anticoagulants, Inc. worldwide. In February 2007,
noClot-400 received a CE Mark for distribution in the European Union.
noCLOT-400 is a United States Pharmacopeia formulated product containing 4 milliliters of ACD-A. noCLOT brand anticoagulants prevent the coagulation of blood by virtue of their citrate
ion'ss ability to chelate the ionized calcium present in blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of
ionized calcium, blood clotting is prevented.
noCLOT-400 is marketed and distributed exclusively by Citra Anticoagulants, Inc.
About Citra Anticoagulants:
Headquartered in Braintree, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more about
Citra and our products, visit our website at www.CitraAnticoagulants.com.
Contact:
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
Trina Saintus, Team Customer
Tel: 781-848-2174
800-299-3411(USA only)
Fax: 781-848-6781